Publications To Date


    Filter Publications

    PAGE 1 OF 11 | DISPLAYING 1 - 15 OF 152 RESULTS

    Mukhopadhyay A. et. al., Characterization of abscopal effects of intratumoral electroporation-mediated IL-12 gene therapy,, Gene Therapy, Oct 15, 2018

    Cristescu R. et. al., Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy, 10.1126/science.aar3593 , Science, Oct 12, 2018

    Angelova M. et. al., Evolution of Metastases in Space and Time under Immune Selection,, Cell, Oct 11, 2018

    Medler T.R. et. al., Complement C5a Fosters Squamous Carcinogenesis and Limits T Cell Response to Chemotherapy,, Cancer Cell, Oct 08, 2018

    Amaria R.N. et. al., Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma,, Nature Med., Oct 08, 2018

    Blabk C.U. et. al., Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma,, Nature Med., Oct 08, 2018

    Chang Y.H. et. al., Computational measurement of tumor immune microenvironment in gastric adenocarcinomas,, Sci. Reports, Sep 17, 2018

    Foulds G.A. et. al., Immune-Phenotyping and Transcriptomic Profiling of Peripheral Blood Mononuclear Cells From Patients With Breast Cancer: Identification of a 3 Gene Signature Which Predicts Relapse of Triple Negative Breast Cancer, 10.3389/fimmu.2018.02028, Front Immunol., Sep 11, 2018

    Su B. et. al., hsa-miR-24 suppresses metastasis in nasopharyngeal carcinoma by regulating the c-Myc/epithelial-mesenchymal transition axis, 10.3892/or.2018.6690, Oncol Rep., Sep 07, 2018

    Sugio T. et. al., Microenvironmental immune cell signatures dictate clinical outcomes for PTCL-NOS, 10.1182/bloodadvances.2018018754, Blood Adv., Sep 07, 2018

    Jiang P. et. al., Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response,, Nature Med., Aug 20, 2018

    Chakravarthy A. et. al., Pan-cancer deconvolution of tumour composition using DNA methylation,, Nature Commun., Aug 13, 2018

    Kim S-S. et. al., Combination with SGT-53 overcomes tumor resistance to a checkpoint inhibitor, 10.1080/2162402X.2018.1484982, Oncoimmunology, Aug 01, 2018

    Polumuri S.K. et. al., Aggregates of IVIG or Avastin, but not HSA, modify the response to model innate immune response modulating impurities,, Sci. Reports, Jul 31, 2018

    Owens G.L. et. al., Ex vivo expanded tumour-infiltrating lymphocytes from ovarian cancer patients release anti-tumour cytokines in response to autologous primary ovarian cancer cells, 10.1007/s00262-018-2211-3, Cancer Immunol. Immunother., Jul 23, 2018